Background Immune checkpoint inhibitor (ICI) therapies have revolutionized oncology, but identifying patients who benefit remains a challenge, particularly in populations where ICIs are not the standard of care, including microsatellite stable colorectal cancer (MSS CRC) and rare solid cancers. We evaluated real-world performance of the Immune Profile Score (IPS), a validated DNA- and RNA-based molecular signature, in these cohorts. Methods In an exploratory analysis, we analyzed two real-world cohorts: 1) MSS CRC; and 2) MSS, tumor mutational burden-low rare solid cancers treated with off-lab
Multimodal Immune Profile Score (IPS) as a Pan-Cancer Biomarker for Stratifying Outcomes of Immune Checkpoint Inhibitor Benefit in Microsatellite Stable Colorectal Cancer and Rare Solid Tumors
calendar_today
October 9, 2026
person
Ting-Lin, M. A., Antonarakis, E. S., Wang, X., Erbe, R., Zander, A. D., Liu, Y., Jin, A., Vidal, G. A., Haake, S. M., Stein, M. M., DeSantis, D. F., Beauchamp, K. A., Campbell, M. E., Cohen, E. E. W., Hyun, S. W., Kelly, R. J., Kalyan, A., Bashir, B., Rimel, B. J., Herzog, T. J., Chiou, V. L., Sangli, C., Nimeiri, H., Carlson, J., Simeone, D. M., Strickler, J. H.
domain
medrxiv